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A B S T R A C T
Purpose
Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC)
who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression,
microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and
overall survival in CC. The objective of this study was to further validate ColDx using formalin-fixed,
paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581.
Patients and Methods
C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no
survival benefit. Under an initial case-cohort sampling design, a randomly selected subcohort (RS)
comprised 514 patients from 901 eligible patients with available tissue. Forty-nine additional patients
with recurrence events were included in the analysis. Final analysis comprised 393 patients: 360 RS
(58 events) and 33 non-RS events. Risk status was determined for each patient by ColDx. The Self-
Prentice method was used to test the association between the resulting ColDx risk score and RFI
adjusting for standard prognostic variables.
Results
Fifty-five percent of patients (216 of 393) were classified as high risk. After adjustment for prognostic
variables that included mismatch repair (MMR) deficiency, ColDx high-risk patients exhibited sig-
nificantly worse RFI (multivariable hazard ratio, 2.13; 95% CI, 1.3 to 3.5; P , .01). Age and MMR
status were marginally significant. RFI at 5 years for patients classified as high risk was 82% (95%
CI, 79% to 85%), compared with 91% (95% CI, 89% to 93%) for patients classified as low risk.
Conclusion
ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors,
includingMMR deficiency. ColDx could be incorporated with the traditional clinical markers of risk to
refine patient prognosis.
J Clin Oncol 34:3047-3053. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Stage I colon cancer (CC) is treated with sur-
gery alone, and patients with stage III CC are
routinely offered adjuvant chemotherapy; how-
ever, the optimal clinical management of patients
with stage II CC is not clearly defined. Stage II CC
accounts for approximately 25% of patients with
CC, and the 5-year survival rate is approximately
75% to 80%, with 15% to 20% of patients expe-
riencing disease recurrence.1 Current guidelines2,3
recommend adjuvant chemotherapy for patients
with stage II CC with high-risk features such as
T4 stage, high tumor grade, inadequate number
of nodes sampled, positive or unknown margins,
lymphovascular and perineural invasion, bowel
obstruction, and perforation. However, a num-
ber of studies have suggested that these histo-
pathological and clinical markers are limited in
their prognostic power.4,5 These limitations have
prompted efforts to identify molecular markers to
guide the clinical management of patients with
stage II CC. Although some molecular markers,
such as loss of heterozygosity and p53 mutational
status, require more evidence to establish their
© 2016 by American Society of Clinical Oncology 3047
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clinical utility as prognostic markers, assessment of microsatellite
instability status has been adopted into clinical practice.3 Several
gene signatures have also been shown to be independently as-
sociated with clinical outcome in patients with stage II CC.6-10
One such gene expression signature, the ColDx assay, can be
applied to formalin-fixed paraffin-embedded (FFPE) tissue col-
lected at the time of diagnosis and has previously been shown to be
prognostic for recurrence-free interval (RFI) and overall survival
(OS) both independent of, and superior to, standard pathologic
features.6 The gene expression signature was developed in two
stages. Stage one involved creation of a Colorectal Cancer Disease-
Specific Array that included genes specifically expressed in human
colorectal cancers.11 The Colorectal Cancer Disease-Specific Array
content (61,528 total probe sets) was generated by a combination
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of high-throughput sequencing, public database mining, and ex-
perimental investigation and was optimized to enable profiling of
RNA extracted from fresh and FFPE samples. A set of 215 human,
stage II colorectal cancers with known outcome data were iden-
tified as a training set and used to develop a 634-probe set, partial
least squares prognostic signature, specific for high risk of recurrence.
The probe sets and statistical methods used were previously de-
scribed, and statistically significant pathways were identified.6 The
analytical properties of this assay have also been reported.12 The assay
was developed and intended for use on FFPE, a commonly used,
standard method of tumor tissue preservation.
The Cancer and Leukemia Group B (CALGB), now the Alliance
for Clinical Trials in Oncology (Alliance), conducted a randomized
phase III clinical trial (C9581) of 1,738 patients with stage II CC
without high-risk features, which concluded that adjuvant edre-
colomab did not significantly increase overall survival compared
with observation only.13 The tissue and data from this clinical trial
were archived for the purpose of biomarker analysis and thus
provided a resource for validation of prognostic molecular markers
in a large cohort of patients with stage II CC. The objective of this
study was to use the C9581 trial samples to further assess the utility
of the ColDx assay to classify patients with stage II CC as low or high
risk of recurrence within 5 years postsurgery.
PATIENTS AND METHODS
Patients
Eligibility requirements for enrollment to the C9581 study have been
reported previously.12 Institutional review board approval and patient in-
formed consent were required at each participating institution. The study
excluded patients with high-risk features, and the overall risk of recurrence
observed in the study was 14.6% at 5 years.13 The eligibility requirements for
the current study included: enrollment in C9581 with available FFPE tissue
and patient consent for use of this tissue; a primary diagnosis of stage II
adenocarcinoma of the colon; colon surgery with curative intent; negative
surgical margins; no nonprotocol, postoperative therapy before recurrence;
no preoperative therapy within 1 year of surgery; no local or regional re-
currence only. Patients with rectal cancer were not eligible.
Of 1,454 patients who were eligible for the study, FFPE tissue was
available for analysis from 901 patients. Among the 901 eligible patients
with available tissue (Figs 1A and 1B), minimum follow-up time was
2.9 months and maximum follow-up time was 12.1 years. The incidence
rate was 0.020 recurrences per person-year, with 124 (13.8%) RFI events
and 777 (86.2%) censored observations. Median follow-up was 8.1 years
(95% CI, 7.9 to 8.2 years) on the basis of the final clinical data set as of
December 4, 2009.
Data from eligible patients treated on C9581 with available samples
were uniquely coded and analyzed in a blinded fashion for gene ex-
pression. All statistical analyses involving the clinical data were conducted
by Alliance statisticians.
Pathology
During the conduct of C9581, FFPE primary tumor and normal
colon were obtained for each case, with histology confirmed by central
pathology review. Staging was conducted as previously described.13 Of the
samples within the final study cohort for this investigation, 85% had
a viable tumor volume of $ 50%. Specimens with a tumor volume of
, 50% were macrodissected for inclusion within the study. DNA mis-
match repair (MMR) status was assessed by immunohistochemistry
for mut L homolog 1 (MLH1) and mut S homolog 2 (MSH2), also as
previously described.7
Gene Expression Profiling
Total RNA was extracted from two 10-mm sections obtained
from a single representative FFPE tissue block, amplified and hy-
bridized to the Almac Colorectal Cancer disease-specific microarray in
Table 1. Patient and Tumor Characteristics for 393 Patients in the Study Cohort, 1,061 Eligible Patients Not in the Study Cohort, and Total 1,454 Eligible Patients From
the Parent Trial
Characteristic Value
Eligible Included in Study (n = 393)*
Eligible Patients Not Included in Study
(n = 1,061)*
Parent C9581 Trial Eligible Patients
(N = 1,454)*
No. (%)†‡ No. (%)†‡ No. (%)†
Age Years 64 (23) 64 (13) 64 (11)
Sex Male 209 (53) 554 (52) 763 (52)
Race/ethnicity White 357 (91) 971 (91) 1,328 (92)
(n = 392) (n = 1,057) (n = 1,449)
Treatment arm Edrecolomab 192 (49) 528 (50) 720 (50)
T stage T4 18 (5) 35 (3) 53 (4)
Nodes examined No. 14.5 (17) 14.7 (12) 14.6 (9)
Perineural invasion Present 10 (2) 27 (3) 37 (3)
(n = 391) (n = 1,056) (n = 1,447)
Lymphovascular invasion Present 47 (11) 115 (11) 162 (11)
Tumor grade High 67 (17) 148 (14) 215 (15)
(n = 1,054) (n = 1,447)
Obstruction or perforation Present 6 (2) 20 (2) 26 (2)
(n = 1,060) (n = 1,453)
Tumor location Proximal 244 (62) 634 (59) 878 (60)
(n = 1,060) (n = 1,453)
MMR status§ Deficient 94 (26) 84 (18) 178 (21)
(n = 377) (n = 456) (n = 833)
Abbreviation: MMR, mismatch repair.
*Sample size unless otherwise specified.
†Denotes mean and standard deviation for age and nodes examined.
‡Percentages weighted to reflect those in the entire eligible cohort (N = 1,454).12
§MMR as determined by immunohistochemistry on mut L homolog 1 (MLH1), mut S homolog 2 (MSH2).
www.jco.org © 2016 by American Society of Clinical Oncology 3049
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a Clinical Laboratory Improvement Amendments (CLIA), New York
State–approved laboratory (Helomics Corporation, Pittsburgh, PA).
The ColDx gene expression signature was used to classify patients as
low or high risk for recurrence by computing a signature score as
described previously.6
Statistical Methods
The primary end point for this study was RFI measured from study
entry (randomization) to distant recurrence or death related to colon
cancer. Patients without distant recurrence or who died of other causes
including second malignancies were censored. Overall survival (any
cause of death) measured from study entry was studied as a secondary
end point.
A case-cohort design was used to compare RFI between patients
with ColDx-predicted low- and high-risk scores.14,15 Under this design,
a randomized subcohort (RS) was selected from 901 eligible patients after
stratification on treatment.16 The recurrent cases that were not selected
randomly were included in the analysis data set. The case-cohort design
was used to maximize cost efficiency by limiting the number of non-
recurrent patient samples to be assayed. Power estimates were de-
termined on the basis of the methods proposed by Cai and Zeng.17 The
initial study cohort comprised a subcohort of 514 patients randomly
sampled, including 75 patients with RFI events and 49 patients with RFI
events outside the RS, resulting in a total of 563 patients (124 patients
with RFI events).
For reasons described in the Appendix (online only), the study was
amended. Power computations were revised on the basis of the following
assumptions: 449 of 901 patients sampled in the RS using a sampling
fraction of 0.4983; a proportion of samples marker positive, p1, of 0.20;
a proportion of events in the full cohort, pD, of 0.1199 (108 of 901).
Under these assumptions, a hazard ratio of 2.05 was detectable with ap-
proximately 80% power. Data from 393 patients were included in the
final analysis.
Patients were categorized as low or high risk coded on the basis of
a prognostic score of 0.4377, fixed before analysis involving patient
outcomes. This threshold was selected after migration of the ColDx assay
from the Affymetrix GeneChip System 3000 7G scanner to the Affymetrix
microarray platform GeneChip System 3000Dx v.2.
The primary hypothesis that the ColDx classification was significantly
associated with RFI independently of known prognostic factors was tested
using a weighted Cox proportional hazards model adjusting for standard
prognostic variables.15 This multivariable analysis included the coded
prognostic score and the following potentially prognostic variables: age at
study entry (years); sex (male, female); T stage (T3, T4); tumor grade (I-II,
III-IV); tumor location (distal, proximal); number of nodes examined
(continuous measure); MMR status (MMR-deficient, MMR-intact) de-
termined by immunohistochemistry for MLH1 and MSH2, in 377 patients
with complete data and 91 RFI events. Patients with missing data on any
variable were omitted from the multivariable analysis. The likelihood ratio
test was used to test the significance of the addition of the prognostic score
to the reduced multivariable model. The association between RFI and only
the coded prognostic score was also tested. Analyses of Schoenfeld residuals
and regression methods were used to assess the proportional hazards
assumption for each variable.
Data analysis was conducted in R using the Survival package by
Therneau (Self-Prentice method)18,19 and in SAS, version 9.2, using the
programming for case-cohort analysis proposed by Barlow et al.20 Two-
sided P values less than .05 were considered significant.
The x2 test was used to test the associations between ColDx and
categorical prognostic factors; the t test was used to test associations with
continuous factors. No adjustment was made for multiple comparisons in
these analyses.
RESULTS
Sample Cohort
An initial cohort of 563 patients, with 124 RFI events, was
selected for the study (comprising 514 patients with 75 RFI events
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Fig 2. Histogram of continuous ColDx signature score units (n = 393); high risk
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Table 2. Univariable Analyses of Prognostic Factors
Factor HR (95% CI) P
Age (continuous) 1.02 (1.00 to 1.04) .03
Sex (male v female) 0.97 (0.62 to 1.50) .89
T stage (T4 v T3) 1.15 (0.37 to 3.57) .80
Nodes examined (continuous) 0.97 (0.95 to 1.00) .05
Tumor grade (high v low) 1.30 (0.75 to 2.25) .34
Tumor location (proximal v distal) 1.11 (0.70 to 1.75) .65
MMR (deficient v intact) 0.56 (0.31 to 1.01) .05
NOTE. n = 393 with 91 RFI events for all variables except n = 377 with 91 RFI
events for MMR.
Abbreviations: HR, hazard ratio; MMR, mismatch repair; RFI, recurrence-free
interval.
Table 3. Primary Analysis: Multivariable Model of ColDx Signature Score and
Potentially Prognostic Covariates of RFI
Factor HR (95% CI) P
ColDx signature score (high risk v low risk) 2.13 (1.3 to 3.5) , .01
Age (continuous) 1.02 (1.00 to 1.04) .07
Sex (male v female) 0.94 (0.59 to 1.47) .78
T stage (T4 v T3) 0.78 (0.20 to 3.0) .72
Nodes examined (continuous) 0.98 (0.95 to 1.01) .11
Tumor grade (high v low) 1.47 (0.82 to 2.6) .19
Tumor location (proximal v distal) 1.24 (0.74 to 2.1) .41
MMR (deficient v intact) 0.55 (0.29 to 1.02) .05
NOTE. n = 377 with 91 RFI events.
Abbreviations: HR, hazard ratio; MMR, mismatch repair; RFI, recurrence-free
interval.
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in the RS and 49 patients with RFI events outside the RS). Tissue
was available from 549 of these patients for analysis. A quality
control (QC) failure arose in a subset of patient samples because of
a reagent fault during the initial analysis, and the study was
subsequently repeated with qualified reagents (Data Supplement).
Of the initial cohort of 549 tissue samples available for
analysis, a total of 156 samples (28.4%) were excluded from the
analysis because of insufficient tissue, total RNA, or poor qual-
ity. Median (range) time between resection and analysis was
13.2 years (11.2 to 16.0 years). The final evaluable data set in the
repeated analysis contained 393 patients, of whom 91 experi-
enced an RFI event (360 patients with 58 RFI events within the
RS; 33 patients with RFI events outside the RS). Figures 1A and
1B depict the flow of patients through the study and reasons
for exclusion.
The demographic characteristics of the C9581 cohort have
been described.7,13 Patient and tumor characteristics for patients
evaluated in the study were similar to those not included and to
those in the subset of all eligible C9581 patients (Table 1).
Association Between ColDx and Prognostic Factors
Results of preprocessing and derivation of the ColDx signa-
ture score were confirmed by the Alliance statisticians. Figure 2
provides a histogram of the distribution of signature scores. At the
prespecified threshold, ColDx classified 55% of patients (216 of
393) as high risk and 45% (177 of 393) as low risk.
Associations between the dichotomized signature score (high
risk, low risk) and the potential prognostic variables in Table 1 were
explored. ColDx was significantly associated with sex (P = .003),
race (P , .001), and MMR status (P , .001) with higher pro-
portions of men (57% v 49%), nonwhite race (73% v 52%), and
MMR intact tumors (56% v 45%) classified as high risk, re-
spectively. Associations with Tstage, lymphovascular invasion, and
tumor location were marginally significant (Appendix Table A1).
Association Between ColDx and Recurrence Risk
Results of univariable analyses of individual prognostic factors
and RFI are given in Table 2. The primary test of hypothesis was the
assessment of the ColDx score in the presence of conventional
prognostic factors (Table 3). ColDx score was significantly asso-
ciated with RFI after adjustment for other prognostic factors
(hazard ratio [HR], 2.13; 95% CI, 1.3 to 3.5; P , .01) in multi-
variable analysis and was the prognostic factor most strongly as-
sociated with RFI (P , .01) in this data set. Age and MMR status
were of borderline significance. The ColDx signature score con-
tributed significantly to the reduced (prognostic variables only)
model (likelihood ratio test, P , .001). No major deviations from
proportional hazards were observed on the basis of the Schoenfeld
residuals and regression models methods.
ColDx high-risk patients also had a significantly shorter RFI
relative to ColDx low-risk patients in an unadjusted analysis, with
an HR of 2.03 (95% CI, 1.3 to 3.3; P , .01). The recurrence-free
probability at 5 years for patients classified as high risk by the
ColDx score was 82%, with a 95% CI of 79% to 85%, compared
with 91% with a 95% CI of 89% to 93% for patients predicted as
low risk (Fig 3).
OS by ColDx score is illustrated in Figure 4. A marginally
significant association was observed after adjustment for other
prognostic factors in multivariable analysis (OS HR, 1.74; 95% CI,
0.97 to 3.1; P = .06).
DISCUSSION
Given the lower rates of recurrence among patients with stage II
CC, there is reluctance to subject patients to potential toxicity and
other treatment complications with little evidence of treatment
benefit from adjuvant therapy. Current guidelines indicate that
adjuvant therapy may be most appropriate for patients with high-
risk disease characteristics.3 Substantial effort has been devoted to
identifying a higher-risk patient subset under the assumption that
patients at high risk of recurrence would be the most likely to
benefit from adjuvant therapy. ColDx is one of several assays that
have been reported to reliably stratify patients with colon cancer
into groups at high and low risk of disease recurrence.
The ColDx assay has previously been shown to be an in-
dependent prognostic factor for RFI in stage II CC.6 In this second
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Fig 3. Weighted Kaplan-Meier plot of recurrence-free interval by ColDx signature
score dichotomized at the prespecified cut point, 0.4377; 62 and 29 events ob-
served for high and low risk, respectively.
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independent prospectively designed study, the ColDx assay was
again demonstrated to be significantly associated with RFI in the
stage II colon cancer C9581 cohort and to be the most significant
prognostic factor in multivariable analysis, in the presence of
other prognostic factors, inclusive of MMR status. The data and
samples collected as part of the C9581 study protocol were
obtained from patients who were uniformly treated and well
characterized. As such, this cohort provided an invaluable re-
source for objective assessment of novel prognostic markers
such as the ColDx assay.
However, a limitation of this study was the age of the tissue
samples, which may have contributed to the high proportion of
assay failures. (A maximum attrition rate of 10% was originally
expected on the basis of experience in a number of prior studies.)
On average, the length of time between patient resection and assay
analysis was 13.2 years. In addition, results of the first assay series
were affected by a reagent failure in a subset of patient samples,
which was discovered only after the first statistical analysis was
conducted. A plan to salvage the validation and maintain the
integrity of the study was developed in conjunction with the
National Cancer Institute Cancer Therapy Evaluation Program and
incorporated into the protocol. Under this plan, specimens were
returned to the Alliance Pathology Coordinating Office, relabeled,
and reanalyzed by Helomics Corporation. The final statistical
analysis was conducted on the resulting expression data. This
process was transparent, and we are confident in the final results.
The study demonstrated that patients within the C9581 co-
hort predicted as high risk by the ColDx assay have a recurrence-
free probability of 82% (18% probability of recurrence within
5 years) compared with 91% (9% probability of recurrence within
5 years) for patients predicted as low risk with an HR after
multivariable analysis of 2.13. This compares favorably with the
previously reported clinical performance of the assay, where it was
demonstrated to predict high-risk patients with an HR of re-
currence of 2.53 and an HR of cancer-related death of 2.21 in an
independent validation data set.6 The ColDx assay was significantly
associated with RFI in this study (P , .01), providing greater
prognostic value than standard clinical markers, including age
(P = .07), number of nodes examined (0.11), and, notably, MMR
status (P = .05). Analysis of these clinical markers is currently the
primary means by which clinicians determine the clinical man-
agement of patients with stage II colon cancer.
The prognostic performance of ColDx is likely derived from
its relationship to biologic pathways previously reported to dif-
ferentiate between good and poor prognosis in colon cancer via
promotion of tumor growth, invasion, and metastasis that are not
accounted for by traditional prognostic factors.6 In addition, al-
though ColDx is a significant predictor of RFI in its own right, the
addition of the ColDx score significantly contributes to a prog-
nostic model including all clinical covariates (likelihood ratio test,
P , .001), which demonstrates its additive contribution.
There have been several prognostic gene expression assays
for stage II colon cancer.7-10 Only the 12-gene colon cancer
recurrence score is comparable to ColDx, because it has also been
developed to work with FFPE tissue and has undergone in-
dependent validation using the stage II C9581 sample cohort.7
The 12-gene colon cancer recurrence score was also found to be
the most significant prognostic factor among patients studied
from C9581 (HR, 1.68; 95% CI, 1.18 to 2.38; P = .004), with the
HR calculated on a continuous scale for a 25-unit increase in the
score. In the subset of 271 patients for whom data are available
from both assays, there is low correlation between the contin-
uous scores (R = 0.18; 95% CI, 0.06 to 0.29). Although there is
some overlap, it does not seem that the signatures are measuring
the same thing or identifying the same patients as high risk.
Further analysis is being conducted in this patient subset.
Prognostic assays, such as ColDx, would have enhanced
clinical utility if they were also predictive of response to therapy in
colon cancer.21 Other than a marginal treatment effect in the Quick
and Simple and Reliable (QUASAR) trial,22 there have never been
convincing data showing benefit for adjuvant therapy in any study
of stage II disease for CC, including C9581. A retrospective subset
analysis of the stage II cohort in Intergroup 0035 suggested that
fluorouracil therapy might be beneficial in patients with clinical
high-risk factors, such as T4 lesions, obstruction, inadequate nodal
sampling, and perforation.23 Although that hypothesis-generating
observation has never been validated in a prospective manner, the
practice has been embraced and incorporated into guidelines and
clinical care. To support clinical utility, a direction for future re-
searchwould be to show that prognostic gene expression signatures
are also predictive for treatment efficacy.
In summary, the ColDx assay has now been prospectively
validated for a second time as a prognostic marker for patients with
stage II colon cancer and in this patient subset superior to current
prognostic markers such as T stage, nodal sampling, and MMR
status. This study is then an external validation of the prognostic
value of the ColDX assay. Thus, ColDx assay results could be
incorporated with the traditional clinical markers of risk to refine
prognosis. Future studies could be designed to demonstrate the
potential for treatment benefit among high-risk patients defined by
the ColDx risk score.
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Appendix
Administrative Summary of Study Progress
Selection of initial study sample. Five hundred fourteen patients were randomly selected from the available 901 patients meeting
the entry criteria. Seventy-five patients meeting the recurrence end point were included in the random component of the study
sample. Under the case-cohort design, the remaining 49 patients meeting the recurrence end point were also part of the study
sample. A total of 563 patients were identified for potential inclusion in the study. Five hundred forty-nine patient samples were
provided to Helomics Corporation. There were 14 blocks that were either missing or unable to be cut because they were insufficient.
Microarray analysis results. Of the 549 samples provided by the Alliance, sufficient total RNA was extracted to allow for gene
expression profiling of 520 samples. Among the 29 samples that were not profiled by gene expression, six were unable to be
extracted because of lack of tissue availability and 23 because of insufficient RNA. Of these 520 samples, 510 samples were
hybridized to a microarray generating raw data (CEL files). Ten samples were not hybridized to a microarray because of insufficient
cDNA. Of these 510 samples with microarray data generated, 488 passed ColDx quality control (QC) metrics (a total of 22 QC
failures).
An Excel file containing the following data fields was provided to the Alliance for the 510 samples that generated microarray
data, including the 22 QC failures: Alliance Pathology Coordinating Office Number; Almac ID assigned to each sample by Almac
(for correlation to raw CEL files); ColDx signature score; dichotomized clinical call (low risk, high risk, QC failure). The subgroup
of 488 samples passing ColDx QC metrics comprised 449 samples, including 69 events in the randomized sample and 39 events
outside of the randomized sample.
Statistical analysis of ColDx data. Results of the statistical analysis were not expected. To verify that the results were correct, the
laboratory and clinical data merge, recurrence-free interval end points, and statistical analyses were reviewed. Patient-level data
were provided to Almac for exploration of potential issues related to QC, macrodissection, and other laboratory procedures. In this
process, a strong batch effect related to a specific reagent lot number (1201176-B) was noted in a subset of samples. It was concluded
that a lower-than-expected hazard ratio was observed overall because of the reagent failure in this subset. The reagent lot batch effect
was observed at the global gene expression level (principal component analysis), and this effect persisted through to the signature
score. Other technical factors were also evaluated and eliminated as causes.
A plan to salvage the validation and maintain the integrity of the study was developed in conjunction with National Cancer
Institute-Cancer Therapy Evaluation Program and incorporated into the protocol. Under this plan, all specimens were to be
returned to the Alliance PCO, relabeled, and reanalyzed by Helomics Corporation, in a blinded fashion. It was agreed that initial
assessments of patients (514 in the randomly selected subcohort [RS], stratified by treatment) would not be used, and the final
statistical analysis would be conducted on the expression data resulting from reanalysis of the specimens.
Residual material was identified for 524 samples, which were subsequently relabeled, reordered, and reassayed with reagents
that passed QC; 36 had insufficient material and 95 failed ColDx QC. The final set of samples with new ColDx assay values
comprised 393 patients (360 in the randomly selected subcohort, with 58 recurrence-free interval events and 33 events outside
the RS).
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Table A1. Univariable Analyses of Prognostic Factors and ColDx Score (n = 393)
Factor Percent High Risk* P†
Age (mean age; high v low risk) 64 v 63 years .43
Sex (male v female) 57% v 49% .003
Race (white v other) 52% v 73% , .001
Treatment (edrecolomab v observation) 53% v 54% .66
T stage (T4 v T3) 65% v 53% .04
Nodes examined (mean No. of nodes; high v low risk) 14 v 14 nodes .89
Perineural invasion (absent v present) 53% v 60% .46
Lymphovascular invasion (absent v present) 52% v 63% .01
Tumor grade (high v low) 53% v 53% .95
Tumor location (proximal v distal) 51% v 57% .03
Obstruction perforation (absent v present) 53% v 67% .17
MMR (deficient v intact) 45% v 56% , .001
Abbreviation: MMR, mismatch repair.
*Except for continuous variables age and number of nodes examined, where means are given.
†x2 test except for continuous variables, where the t test was used.
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